Viscosupplementation Market Size & Share, by Product (Single Injection, Three Injections, Five Injections); Application (Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis); Source (Animal, Non-Animal); End-user (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Retail Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 4381
  • Published Date: Feb 17, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2033

Viscosupplementation Market size is poised to cross USD 10 Billion by the end of 2033, growing at a CAGR of 9% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of viscosupplementation was USD 4 Billion. The growth of the market can be attributed to the escalating prevalence of osteoarthritis across the globe, owing to the shift of the population towards unhealthy lifestyles and consumption of processed food which in turn is expected to foster arthritis cases. Arthritis is a condition in which people get swelling or inflammation in joints and more than 100 conditions are described by arthritis that affects tissues around joints and other tissues connected to it. For instance, in 2019, there were approximately 526.90 million osteoarthritides (OA) occurrences worldwide. The healthcare provider injects hyaluronic acid into the joints during viscosupplementation treatment to reduce swelling and any sort of pain in the joints.

Osteoarthritis patients have lower levels of hyaluronic acid in their joints, which causes pain. Therefore, a proper infusion of hyaluronic acid delivers optimum results in the elasticity of knee cartilage. It was observed in clinical research that, hyaluronic acid (HA) is a widely known high molecular weight natural glycosaminoglycan consisting of repeating units of D-glucuronic acid and N-acetylglucosamine disaccharide linked by biopolymer B-(1-4) and B-(1-3) glycosides. HA promotes cartilage matrix synthesis and improves cartilage elasticity and humidity. Several orthotic devices, casts, and splints are also utilized to treat the condition of osteoarthritis. It also prevents chondrocyte apoptosis and increases proteoglycan synthesis. As a result, HA is essential for avoiding cartilage erosion and reducing synovial inflammation. In OA patients, the rate of depolymerization and clearance of endogenous HA in joints is higher than normal, which lessens not only the density and molecular weight of HA but also the elastic viscosity of the synovial fluid.

Get more information on this report: Request Free Sample PDF

Viscosupplementation Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Geriatric Population with Severe Arthritis–According to the World Health Organization (WHO), the global population of people over 60 is projected to increase by 1.4 billion by 2030 globally.
  • Growing age brings lots of health issues in elderly people. One of the most common issues they face is
  • bone and joint-related issues i.e., osteoarthritis, osteoporosis, and others that result in difficulty moving walking problems, and so on. A large number of elderly people become completely dependent on personal mobility devices owing to the difficulty of small transportation which further increases the expense of these devices. It is a well-known fact that joint movement becomes less flexible and stiffer as the person ages. The amount of lubricating fluid decreases over time in joints. Therefore, the growing prevalence of the geriatric population is leading to the demand for viscosupplementation treatment.
  • Increasing Prevalence of Obesity - Obesity is anticipated to affect nearly 1 billion people worldwide by 2030. Obesity causes severe joint issues since joint pain is remarkably associated with body weight and being overweight increases the pressure on joints, especially on knees, which can break down the cartilage.
  • Spike in Autoimmune Diseases to Boost the Market Growth – For instance, by the end of 2021, autoimmune diseases affected approximately 24 million individuals in the United States.
  • Growing Healthcare Investment Across the Globe – As per the World Economic Forum, worldwide, ~USD 44 billion was raised in health innovation in 2021 on its own twice as often as in 2020 and merger and acquisition of health and health tech companies improved by 50%.
  • Growing Per Capita Income – According to the World Bank, in 2021, global annual per capita income increased by 4.8%, compared to 1.5% in 2019. Growth in the per capita income increases the spending capacity of the population, especially on health issues, where people are becoming more aware of receiving proper treatment in time.


  • High Cost of Viscosupplementation Treatment – Viscosupplementation treatment requires a lot of high-definition equipment and technology. Additionally, the cost of HA injection is also very high and this may affect the trend and awareness of viscosupplementation in common people negatively. As a result, the cost of this treatment is expected to hamper the growth of viscosupplementation market over the forecast period. 
  • Associated side effects Such as Site Pain and Swelling
  • Lack of Technical Proficiency and Awareness

Viscosupplementation Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

USD 4 Billion

Forecast Year Market Size (2033)

USD 10 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Viscosupplementation System Segmentation

Application (Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis)

The global viscosupplementation market is segmented and analyzed for demand and supply by application into knee osteoarthritis, shoulder osteoarthritis, hip osteoarthritis, and others. Out of these types of applications, the knee osteoarthritis segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the notably growing prevalence of knee osteoarthritis in people with unhealthy lifestyles across the globe and a rising geriatric population that are prone to knee problems. It was observed that, in 2019, knee osteoarthritis accounted for approximately 60.6% of all prevalent cases globally. Knee osteoarthritis is associated with cartilage breakdown which makes bones rub together. It can be caused by obesity, injuries, and infections. Sports injuries cause a notable number of knee osteoarthritis and other reason such as infections generally cause these issues in people aged above 45. For instance, it was observed that around 3 million children receive sports injuries every year across the globe.

Product (Single Injection, Three Injections, Five Injections)

The global viscosupplementation market is also segmented and analyzed for demand and supply by-products into single injection, three injection, and five injections. Amongst these three segments, the five injections segment is expected to garner a significant share. The segment is expected to grow since it is observed that patients require 5 injections per week to relieve the pain in the joints. Viscosupplementation treatment is reserved until no other option can relieve the pain in joints. The series of injections are repeated every 6 months. As of 2021, the viscosupplementation treatment expenditure was evaluated to be approximately USD 250 million globally. Furthermore, three injection segment is also projected to witness noteworthy growth over the forecast period. Every knee therapy requires 3 weekly injections of hylan G-F 20. For instance, gel and cortisone injections are some of the types of VS therapy injections.

Our in-depth analysis of the global viscosupplementation market includes the following segments:       

              By Product

  • Single Injection
  • Three Injections
  • Five Injections

               By Application

  • Knee Osteoarthritis
  • Shoulder Osteoarthritis
  • Hip Osteoarthritis
  • Others

               By Source

  • Animal
  • Non-Animal

               By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
  • Retail Pharmacies
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Viscosupplementation System Industry - Regional Synopsis

North America Market Forecast

The North American viscosupplementation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market can be attributed majorly to the increasing geriatric population, escalating preference for short treatment schedules, and the growing occurrence of osteoarthritis in the region. According to the data released by the Centers for Disease Control and Prevention, by 2020, more than 32.5 million adults in the United States had osteoarthritis. Furthermore, it was also projected that more than 95 million Americans are living with knee pain and require VS therapies to cure the pain, and more than 25%, summing up to 58 million people, in the United States have arthritis. It is stated that knee pain is the 2nd leading pain to cause of chronic pain in people. For instance, knee pain also affects around 22% of adults in the region. Therefore, viscosupplementation treatment is highly required in the region since arthritis increases work disability. For instance, the cost of Medicare and lost earnings in the region are projected to be around USD 300 billion every year in this region. Hence, all these factors are anticipated to expand the viscosupplementation market size in the region over the forecast period.

Asia Pacific Market Forecast

Furthermore, the viscosupplementation market is also expected to obtain notable growth in the Asia Pacific region of the back higher prevalence of arthritis backed by the significant growth in the geriatric population. For instance, approximately 400 million people in Asia were expected to be aged above 65 in 2020, while China and India accounted for 1 billion each. The number of geriatrics in the region was projected to near 18% higher than in the USA. Geriatrics suffer from severe knee problems. Therefore, this factor is expected to boost the growth of the market in the region over the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Viscosupplementation System Landscape

    • Sanofi S.A.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Anika Therapeutics, Inc.
    • Seikagaku Corporation
    • Smith & Nephew PLC
    • Lifecore Biomedical, Inc.
    • LG Chem Life Sciences Innovation Center, Inc.
    • Fidia Farmaceutici S.p.A.
    • F. Hoffmann-La Roche Ltd
    • Chugai Pharmaceutical Co., Ltd.
    • OrthogenRx, Inc.


In The News

  • Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for its osteoporosis treatment Edirol Tablets 0.5 g/0.75 g (generic name: eldecalcitol, hereafter, Edirol Tablet), a vitamin D3 derivative developed by Chugai based on long-standing research into vitamin D.

  • Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. The main ingredient of HyLink is a cross-linked hyaluronate hydrogel derived from Seikagaku's crosslinking technology.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 4381
  • Published Date: Feb 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing geriatric population and high prevalence of obesity are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2033.

High cost of viscosupplementation treatment is estimated to be the growth hindering factor for the market expansion.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are Anika Therapeutics, Inc., Seikagaku Corporation, Smith & Nephew PLC, Lifecore Biomedical, Inc., LG Chem Life Sciences Innovation Center, Inc., Fidia Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co., Ltd., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, source, end-user, and by region.

The knee osteoarthritis segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Viscosupplementation Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying